Classification of US FDA Inspection at Unit-III of Eugia Pharma Specialities Ltd, Pashamylaram as OAI

The United States Food and Drug Administration (US FDA) inspected Eugia Unit-III, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Phase-III, TSIIC, EPIP, IDA, Pashamylaram, Patancheru Revenue Mandal, Sangareddy District, 502307, Telangana, from January 27 to February 06, 2026. The inspection had concluded with 11 observations.

FDA has now determined that the inspection classification of this facility is "official action indicated" (OAI).

The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1472.25 as compared to the previous close of Rs. 1464.10. The total number of shares traded during the day was 23138 in over 1729 trades.

The stock hit an intraday high of Rs. 1481.00 and intraday low of 1466.00. The net turnover during the day was Rs. 34136142.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 Pharmaceuticals EugiaPharmaSpecialities Unit3 Formulation ManufacturingFacility USFDA OAI